-
Published 9/15/2026
Bittar M, Chalian M, Horbal N, Caplan L, Dubreuil M, Pezeshk P, Stovall R, Kung JY, Gensler LS, Deodhar A, Lambert RGW, Maksymowych WP. What Defines an MRI Considered Indicative of Axial Spondyloarthritis in the Sacroiliac Joints: A Systematic Literature Review. J Rheumatol. 2026 Sep 15. PMID: 42744402.
-
Published 9/1/2026
Dubreuil M, Danve A, Liew JW, Alexander SA, Afinogenova Y, Bittar M, Fraenkel L, Grimshaw A, Kumthekar A, LaValley MP, Magrey MN, Majithia V, Merjanah S, Norton H, Walsh JA, Deodhar A. Spondyloarthritis Research and Treatment Network Recommendations for the Referral of Adults With Chronic Back Pain and Suspected Axial Spondyloarthritis to a Rheumatologist. ACR Open Rheumatol. 2026 Sep; 8(9):e90129. PMID: 42689760.
-
Published 8/7/2026
Nikiphorou E, Tillett W, Deodhar A, Dubreuil M, Gossec L, Hwang M, Lubrano E, Machado PM, Rudwaleit M, de Wit M, Kavanagh S, de la Loge C, Ink B, Healy P, Lambert J, Mørup M, Boonen A, Walsh J. Effect of Bimekizumab Treatment on Health Status, Work Productivity, and Productivity Costs Through 3 Years in Axial Spondyloarthritis and Psoriatic Arthritis. J Rheumatol. 2026 Aug 07. PMID: 42386286.
-
Published 5/13/2026
Navarro-Compán V, Kiltz U, Mease PJ, Dubreuil M, Gaffney K, Deodhar A, de la Loge C, Prajapati C, Kavanagh S, Marzo-Ortega H. Bimekizumab treatment for sustained improvements in patient symptoms and health-related quality of life to 3 years in axial spondyloarthritis: results from the BE MOBILE studies and their open-label extension. RMD Open. 2026 May 13; 12(2). PMID: 42128532.
-
Published 12/1/2025
Choufani M, Ghusn W, Dubreuil M, Ermann J. Diversity in Axial Spondyloarthritis Drug Trials: Enrollment by Sex, Race, Ethnicity, and Geographic Region. J Rheumatol. 2025 Dec 01; 52(12):1245-1253. PMID: 40089303.